AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

ICP-332 in Subjects With Non-segmental Vitiligo

RecruitingPhase 2, Phase 3Ages 12 Years - 75 YearsAllBeijing InnoCare Pharma Tech Co., Ltd.
💬

In plain words

What the trial is, and whether it could suit you

This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an phase 2 part and an phase 3 part.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Male or female subjects aged ≥18 years and ≤75 years (Phase II portion). Male or female subjects ≥12 years of age and ≤75 years of age, adolescent subjects must weigh ≥40 kg (Phase III portion). 2. Eligible subjects must meet all of the following criteria at screening and baseline: 1. The clinical diagnosis was non-segmental vitiligo for at least 3 months. 2. Involvement of BSA≥5%. 3. Facial involvement BSA≥0.5%. 4. F-VASI≥0.5 and T-VASI between 5 and 50. 5. Active or stable non-segmental vitiligo was present at both screening and baseline visits. 3. Women of childbearing potential (WOCBP) and Men must agree to contraception. 4. Before beginning any screening or study specific procedures, subjects must voluntarily sign informed consent. Exclusion Criteria: 1. Any of the following vitiligo related medical conditions and other skin diseases/conditions. a) Subjects had other types of vitiligo (including but not limited to segmental vitiligo and mixed vitiligo) that did not meet the criteria for active or stable vitiligo described in Inclusion criteria 2. 2. History of any clinically major diseases, with the exception of vitiligo. 3. Pregnant or breastfeeding females. 4. The investigator considers that the subject is not suitable for participation in this study for any reason.
💊

What it tests

  • ICP-332 Tablets
  • ICP-332 Placebo Tablets
📍

Where

45 sites
The First Affiliated Hospital of Wannan Medical College
Wuhu, China
The Second Affiliated Hospital of Wannan Medical College
Wuhu, China
Peking University Third Hospital
Beijing, China
Beijing Chao-yang Hospital,Capital Medical University
Beijing, China
Beijing Tongren Hospital
Beijing, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Chongqing Traditional Chinese Medicine Hospital
Chongqing, China
Union Hospital affiliated to Fujian Medical
Fuzhou, China

…and 37 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy